MA56535A - Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées - Google Patents

Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Info

Publication number
MA56535A
MA56535A MA056535A MA56535A MA56535A MA 56535 A MA56535 A MA 56535A MA 056535 A MA056535 A MA 056535A MA 56535 A MA56535 A MA 56535A MA 56535 A MA56535 A MA 56535A
Authority
MA
Morocco
Prior art keywords
hbv
vaccines
hepatitis
virus
self
Prior art date
Application number
MA056535A
Other languages
English (en)
Inventor
Daniel Boden
Helen Horton
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56535A publication Critical patent/MA56535A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA056535A 2019-06-20 2020-06-19 Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées MA56535A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863961P 2019-06-20 2019-06-20
US202063006925P 2020-04-08 2020-04-08

Publications (1)

Publication Number Publication Date
MA56535A true MA56535A (fr) 2022-04-27

Family

ID=71833364

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056535A MA56535A (fr) 2019-06-20 2020-06-19 Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Country Status (7)

Country Link
US (1) US20220313815A1 (fr)
EP (1) EP3986458A1 (fr)
AU (1) AU2020298267A1 (fr)
CA (1) CA3143632A1 (fr)
MA (1) MA56535A (fr)
TW (2) TWI769467B (fr)
WO (1) WO2020255055A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021236068A1 (en) 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
EP4196128A4 (fr) 2020-08-14 2024-06-12 Arcturus Therapeutics, Inc. Méthode de lyophilisation de nanoparticules lipidiques
TW202313967A (zh) * 2021-07-30 2023-04-01 美商亞克圖羅斯醫療公司 Ｒｎａ疫苗
CN115960922A (zh) * 2021-10-09 2023-04-14 吴可行 自复制rna分子设计及其应用
CN120548367A (zh) 2022-11-18 2025-08-26 波士顿大学董事会 自复制rna及其用途
IL326711A (en) * 2023-08-24 2026-04-01 BioNTech SE Systems and compositions comprising highly active trans-amplifying replicases
WO2025088152A1 (fr) 2023-10-27 2025-05-01 Ziphius Nv 5'utr modifiées

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
EP2591114B1 (fr) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation de grands mammifères à l'aide de faibles doses d'arn
CA2841047A1 (fr) 2011-07-06 2013-01-10 Novartis Ag Compositions immunogenes et leurs utilisations
TWI623618B (zh) * 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
AU2017241925B2 (en) 2016-03-28 2022-01-13 Ichor Medical Systems, Inc. Method and apparatus for delivery of therapeutic agents
KR102718353B1 (ko) 2016-10-17 2024-10-15 얀센 파마슈티칼즈, 인코포레이티드 재조합 바이러스 레플리콘 시스템 및 그의 용도
CA3045650A1 (fr) 2016-12-05 2018-06-14 Janssen Pharmaceuticals, Inc. Compositions et methodes d'activation d'expression genique
GB201705765D0 (en) * 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd HBV vaccine
AU2018390825A1 (en) * 2017-12-19 2020-06-18 Ichor Medical Systems, Inc. Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
CN111836641A (zh) * 2017-12-19 2020-10-27 杨森科学爱尔兰无限公司 乙型肝炎病毒(hbv)疫苗及其用途
KR20200100745A (ko) * 2017-12-19 2020-08-26 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물
WO2020076775A1 (fr) * 2018-10-08 2020-04-16 Janssen Pharmaceuticals, Inc. Réplicons à base d'alphavirus pour l'administration d'agents biothérapeutiques

Also Published As

Publication number Publication date
TWI828168B (zh) 2024-01-01
US20220313815A1 (en) 2022-10-06
WO2020255055A1 (fr) 2020-12-24
EP3986458A1 (fr) 2022-04-27
CA3143632A1 (fr) 2020-12-24
TW202235428A (zh) 2022-09-16
AU2020298267A1 (en) 2022-02-17
TW202108598A (zh) 2021-03-01
TWI769467B (zh) 2022-07-01

Similar Documents

Publication Publication Date Title
MA56535A (fr) Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
MA51311A (fr) Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
MA50520A (fr) Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb)
MA51292A (fr) Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)
Killip et al. Influenza virus activation of the interferon system
EP2519266A4 (fr) Vaccins à base d'adn infectieux contre le virus du chikungunya
AU2020219355A1 (en) RNAi agents for Hepatitis B virus infection
MA46535A (fr) Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
WO2008099189A3 (fr) Virus de l'herpès simplex et procédés de réplication virale
IL307823A (en) Negative-strand rna viral vector and plant genome editing method without transformation
IL288019A (en) Preparations and methods for treating hepatitis b virus infection
MA51312A (fr) Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)
EP4022086C0 (fr) Compositions et procédés pour l'amplification et la détection de l'arn du virus de l'hépatite b, comprenant l'arn du vhb transcrit à partir de adnccc
GB201915905D0 (en) Viruses with modified capsid proteins
IL281698A (en) Monomer and multimeric anti-hbv agents
DK4069729T3 (da) Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
MA56524A (fr) Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
EP3618859A4 (fr) Séquences de gènes du virus de l'hépatite c et leurs méthodes d'utilisation
IL313397A (en) Omni-103 crispr nuclease-rna complexes
EP2484376A4 (fr) Méthode, trousse, plasmide et composition pour induire une réponse immunitaire contre le virus de la dengue, au moyen de vaccins à adn et de virus chimériques
HRP20090230T1 (hr) Replikacijski-defektni rna virusi kao cjepiva
EP3515929A4 (fr) Vaccins thérapeutiques contre le virus de l'hépatite b
IL290924A (en) Vaccines for hepatitis b virus
MA55494A (fr) Molécules de liaison spécifiques pour la protéine d'enveloppe du virus de l'hépatite b (vhb)
WO2007046839A3 (fr) Nouveaux vaccins a base de virus vivant